Secondary Myelofibrosis Recruiting Phase 2 Trials for Mechlorethamine (DB00888)

IndicationStatusPhase
DBCOND0030964 (Secondary Myelofibrosis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02251821JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisTreatment
NCT04384692Peritransplant Ruxolitinib for Patients With Primary and Secondary MyelofibrosisTreatment
NCT04370301Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary MyelofibrosisTreatment
NCT04339101Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell TransplantationTreatment